Amarin Corporation PLC Announces Submission of a Supplemental New Drug Application for BASF as Additional Vascepa® Active Pharmaceutical Ingredient Supplier

BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the late December 2012 submission of a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for BASF as an additional Vascepa® (icosapent ethyl) active pharmaceutical ingredient (API) supplier.